We are live on ! Find out more
IGMS

IGM Biosciences
IGMS

Delisted

IGMS was delisted on the 13th of August, 2025.

Back to rankings

89 hedge funds and large institutions have $316M invested in IGM Biosciences in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 26 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

695% more call options, than puts

Call options by funds: $2M | Put options by funds: $252K

19% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 26

4% less funds holding

Funds holding: 93 → 89 (-4)

6.23% less ownership

Funds ownership: 70.11% → 63.87% (-6.2%)

11% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 19

35% less capital invested

Capital invested by funds: $487M → $316M (-$172M)

Holders
89
Holders Change
-4
Holders Change %
-4.3%
% of All Funds
1.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
17
Increased
31
Reduced
26
Closed
19
Calls
$2M
Puts
$252K
Net Calls
+$1.75M
Net Calls Change
-$5.36M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.72M
2
Millennium Management
Millennium Management
New York
+$6.56M
3
Marshall Wace
Marshall Wace
United Kingdom
+$3.47M
4
Victory Capital Management
Victory Capital Management
Texas
+$1.26M
5
N
Nuveen
North Carolina
+$1.09M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$10.8M
2
EC
EcoR1 Capital
California
-$7.98M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$5.69M
4
Goldman Sachs
Goldman Sachs
New York
-$4.09M
5
WP
Woodline Partners
California
-$3.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
VIA
26
Vident Investment Advisory
Georgia
$882K +$872K +48,946 New
EBA
27
Eagle Bay Advisors
New York
$751K +$121K +6,800 +20%
RJA
28
Raymond James & Associates
Florida
$698K -$23.8K -1,334 -3%
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$695K +$113K +6,364 +20%
E
30
Ergoteles
New York
$694K +$686K +38,500 New
Renaissance Technologies
31
Renaissance Technologies
New York
$638K -$513K -28,800 -45%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$616K +$126K +7,067 +26%
TD Asset Management
33
TD Asset Management
Ontario, Canada
$587K – – –
Simplex Trading
34
Simplex Trading
Illinois
$516K +$511K +28,642 New
JF
35
Jump Financial
Illinois
$470K +$465K +26,059 New
AllianceBernstein
36
AllianceBernstein
Tennessee
$449K +$176K +9,900 +66%
Citadel Advisors
37
Citadel Advisors
Florida
$432K -$525K -29,448 -55%
CSS
38
Cubist Systematic Strategies
Connecticut
$404K +$251K +14,093 +170%
GCP
39
GSA Capital Partners
United Kingdom
$395K -$260K -14,600 -40%
Swiss National Bank
40
Swiss National Bank
Switzerland
$388K +$53.5K +3,000 +16%
PI
41
Putnam Investments
Massachusetts
$371K +$149K +8,356 +68%
Jane Street
42
Jane Street
New York
$363K +$358K +20,110 New
CANY
43
Caxton Associates (New York)
New York
$343K +$339K +19,009 New
NYLIM
44
New York Life Investment Management
New York
$315K +$311K +17,446 New
BCM
45
Bayesian Capital Management
New York
$305K +$301K +16,900 New
State Board of Administration of Florida Retirement System
46
State Board of Administration of Florida Retirement System
Florida
$266K +$263K +14,748 New
PP
47
PDT Partners
New York
$261K -$79K -4,431 -23%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$232K +$65.3K +3,661 +40%
FAM
49
Fred Alger Management
New York
$218K -$1.31M -73,542 -86%
California State Teachers Retirement System (CalSTRS)
50
California State Teachers Retirement System (CalSTRS)
California
$213K +$31.6K +1,775 +18%
1
2
3 4 5

IGMS Hedge Fund Activity: Q2 2022 in Review

89 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in IGM Biosciences (IGMS) for Q2 2022, worth a combined $316M — down 35% from $487M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of IGMS and 17 opened new positions — a net loss of 2 holders — while 26 trimmed existing stakes and 31 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $6.72M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $10.8M sold.

  • 89 institutional investors held IGM Biosciences (IGMS) as of Q2 2022, down from 93 in Q1 2022.
  • Funds reported $316M of IGM Biosciences stock for Q2 2022, down 35% quarter-over-quarter.
  • 17 funds opened new IGM Biosciences positions in Q2 2022 and 19 closed out, a net change of -2 holders.
  • The largest IGM Biosciences buyer in Q2 2022 was T. Rowe Price Associates, an estimated $6.72M added.
  • The largest IGM Biosciences seller in Q2 2022 was Cormorant Asset Management, an estimated $10.8M sold.

Based on aggregated 13F filings for Q2 2022.